Feature

Syngene and Johns Hopkins Partner to Advance Early-Stage Drug Discovery

Collaboration anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

  • By

  • February 25, 2026

  • 2 min

Share

Syngene International, a CRDMO based in Bangalore, India, has partnered with Johns Hopkins University to enhance early-stage drug discovery. This collaboration utilizes Syngene SynVent™, integrating various scientific disciplines to streamline the drug development process. By leveraging Syngene’s Connector model, the partnership aims to connect innovative academic research with strategic investors and partners, accelerating the translation of discoveries into viable therapeutic candidates. This initiative strives to reduce the timeline for developing new medicines.

Original Source(s)

Syngene and Johns Hopkins Partner to Advance Early-Stage Drug Discovery

Collaboration anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

  • February 25, 2026

  • 2 min

Related Content

What Cats Can Tell Us About Cancer

Large-scale feline sequencing study highlights diagnostic and therapeutic targets shared with human cancers

  • February 25, 2026

  • 2 min
Making Laparoscopic Cholecystectomy Safer

Laparoscopic cholecystectomy has become the gold standard for gallbladder removal, with more than 750,000 procedures performed annually in the U.S.

  • by

  • February 24, 2026

  • 3 min
The Most Sensitive Cancer Blood Test Yet

A CRISPR-powered light sensor detected trace amounts of cancer biomarkers in the blood

  • February 24, 2026

  • 2 min